SecBot SecBot
SECBOTREPLAY Home › Report › NRIX

NRIX · Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss)…

Nurix Therapeutics, Inc. · PRESS-RELEASE filed Jul 9, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Jul 9, 2026 at 16:01 ET

Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% miss) following a year-ago quarter that included $30M in license fees. The revenue miss is largely explained by the absence of the prior-year Sanofi license payments, but the operational spend ramp (R&D up 12% YoY) drove net loss to -$89.5M vs -$43.5M. The dominant positive event is the global Roche collaboration for bexobrutideg, which brings a $700M near-term cash infusion (expected closing in Q3) and total potential milestones of $2.3B, dramatically extending the cash runway to ~$1.14B pro-forma and validating the BTK degrader platform across oncology, immunology, and neurology.

  • Revenue $9.0M miss vs consensus $15.3M (-41%); prior year $44.1M included $30M in Sanofi license fees
  • EPS -$0.81 miss vs consensus -$0.72 (-12.5%); prior year -$0.52
  • Net loss -$89.5M vs -$43.5M; R&D spend $87.7M (+12% YoY)
  • Cash/investments $443.5M as of May 31, 2026; pro-forma ~$1.14B after Roche upfront

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access